Skip to main content
. 2020 Sep 22;76(12):1455–1465. doi: 10.1016/j.jacc.2020.07.044

Table 5.

Sex-Specific Incremental Value of Selected Biomarkers Over the Clinical Model

Biomarkers Men
p Value Women
p Value
Risk Estimation Risk Estimation
C-statistic 0.797 (0.784–0.809) 0.815 (0.804–0.827)
LHR 12376 11991
Natriuretic peptides
 C-statistic + NPs 0.803 (0.790–0.815) 0.811 (0.799–0.823)
 Δ C-statistic 0.006 −0.004
 LHR + NPs 12,230 11,908
 LHR chi-square 146 <0.001 83 <0.001
Cardiac troponins
 C-statistic + cTns 0.800 (0.787–0.813) 0.818 (0.806–0.829)
 Δ C-statistic 0.003 0.003
 LHR + hs-Tn 12,309 11,918
 LHR chi-square 67 <0.001 73 <0.001
C-reactive protein
 C-statistic + CRP 0.798 (0.785–0.810) 0.818 (0.806–0.829)
 Δ C-statistic 0.001 0.003
 LHR + CRP 12,367 11,976
 LHR chi-square 9 0.003 15 <0.001

For these analyses, 8,926 men with 879 HF events and 9,328 women with 830 HF events with no missing biomarker measurements were included.

CRP = C-reactive protein; cTn = cardiac troponin; LHR = likelihood ratio test; NP = natriuretic peptide.

Base model includes age, smoking, diabetes mellitus, hypertension, body mass index, atrial fibrillation, myocardial infarction, and presence of left ventricular hypertrophy/left bundle branch block; strata statement included.